Group 1 - The core viewpoint of the article is that Xibei's frozen organic broccoli is of the highest quality on the market, with prices 80% to 120% higher than regular broccoli, and there has never been a case of "two-year-old broccoli" in their supply chain [4][5]. - Xibei's frozen broccoli is exported to Europe, the United States, Japan, and South Korea, and was previously used for the Asian Games, ensuring high standards of food safety through ultra-low temperature freezing technology and cold chain transportation [5]. - The shelf life of exported frozen vegetables is typically 18 to 24 months, but Xibei ensures that their organic broccoli is used within two months, with a current standard of one month [5]. Group 2 - The article mentions that Bilibili (B站) expects users to watch over 83 billion minutes of content from its top 100 creators by 2025, indicating significant engagement on the platform [17]. - AMD has committed to keeping the prices of its Radeon graphics cards within a range that is affordable for average consumers, addressing the issue of skyrocketing prices due to DRAM shortages [10]. - The article highlights that the global largest automotive supplier Bosch is facing financial pressure, with a projected profit margin below 2% for 2025, largely due to restructuring costs [16].

今日热点导览 B站：2025年，用户观看百大UP主内容的总时长超过830亿分钟 首次飞行试验任务失利，星河动力致歉 AMD承诺：将显卡价格控制在普通人能接受的范围内 两部门：商业用房购房贷款最低首付款比例调整为不低于30% 阿里CEO吴泳铭发布新年家书：今年几场大仗很漂亮 追觅创始人俞浩：做出百万亿美金公司是目标，没烧过投资人的钱 TOP3大新闻 贾国龙再发声："从来不存在两岁的西蓝花" 1月18日，西贝董事长贾国龙在朋友圈发布了"回应三"，主要对此前消费者热议的西贝冷冻西蓝花问题进行了回应。 贾国龙提到，西贝选用的冷冻有机无农残西蓝花属市面最高品级区间，其价格比市面普通西蓝花高80%至120%。贾国龙表示："这种西蓝花出口欧美日 韩，曾为亚运会专用，与山姆、盒马等超市的西蓝花同款。采用超低温急冻技术，在不添加任何防腐剂的情况下，有效减缓维生素流失，保留矿物质与膳 食纤维。全程冷链运输，确保最高标准的食品安全"。他还表示，所有出口的冷冻蔬菜保质期多为18至24个月。但在西贝从来不存在什么"两岁的西蓝 花"，西贝的高周转率保证了有机西蓝花在两个月内使用完毕，现在的标准是必须一个月内使用完毕。（每日经济新闻） 贾 ...

Core Viewpoint - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration and will completely exit the Chinese market, ceasing all business activities and supply of rare disease medications, including the only oral drug for Cushing's syndrome, Osilodrostat [1][2] Group 1: Company Actions - Ruikangdi announced the completion of its liquidation process on December 11, 2025, and will terminate all operations shortly [1] - The exit will result in the discontinuation of several rare disease drugs, including Osilodrostat, which was only recently commercialized in China [1][2] - Recordati had high expectations for Osilodrostat's sales in China, where it was priced at approximately 8,000 yuan per box, with an average annual treatment cost of around 200,000 yuan [1] Group 2: Market Challenges - The failure to include Osilodrostat in the national medical insurance directory has been cited as a significant factor in Ruikangdi's decision to exit [3][4] - The market for rare disease drugs in China faces challenges such as high development costs, limited patient populations, and reliance on multi-tiered payment systems, which complicate access to these medications [2][3] - The number of patients purchasing Osilodrostat in domestic pharmacies is estimated to be around 50, highlighting the limited market penetration [2] Group 3: Industry Trends - Ruikangdi's exit reflects a broader trend of multinational pharmaceutical companies reassessing their strategies in the Chinese market, with several companies restructuring or divesting their operations [4][6] - The exit of Ruikangdi and other companies may lead to increased opportunities for domestic pharmaceutical firms and could drive innovation and upgrades within the local industry [6]

Group 1: Policy Changes and Industry Impact - The Ministry of Finance and the State Taxation Administration announced the cancellation of export tax rebates for photovoltaic products starting April 1, 2026, with battery product rebates gradually phasing out, aimed at curbing low-price competition in overseas markets [1][10] - The photovoltaic industry is currently not profitable, and this policy is expected to directly reduce company revenues, causing short-term pain [1][10] - Experts believe that while the policy may help rationalize overseas market prices, addressing the issue of "involution" requires technological breakthroughs and industry self-discipline [1][10] Group 2: Commodity Price Fluctuations - Recent significant increases in tomato prices across multiple regions in China have been observed, with retail prices ranging from 5 to 18 yuan per pound, and wholesale prices rising over 80% year-on-year [1][11] - The price surge is attributed to continuous rainfall during the summer and autumn seasons, leading to plant damage and reduced yields [1][11] - It is expected that prices will significantly decline by late January as new batches of tomatoes come to market [1][11] Group 3: Market Challenges and Company Responses - Shenzhen's Shui Bei and Cheng Xing Silver Tower have been accused of delivery delays, with some merchants claiming losses exceeding 300,000 yuan, and over 350 people in a rights protection group [1][12] - The past year saw a 214% increase in spot silver prices, leading many silver merchants to adopt a "payment before delivery" model, which has raised credit risks due to market volatility [1][12] - Legal experts advise investors to verify qualifications and clarify delivery and refund terms when signing contracts, emphasizing the importance of preserving evidence [1][12] Group 4: Resource Supply and Industry Development - The first shipment of 200,000 tons of iron ore from the world's largest iron ore project, Simandou, has arrived at Zhejiang Shengsi Port, marking the full integration of its supply chain [1][13] - The project, located in Guinea, has a massive reserve and is expected to supply 120 million tons annually once fully operational, significantly enhancing China's direct supply and security of iron ore resources for the steel industry [1][13] Group 5: Economic Indicators and Trends - China's total electricity consumption is projected to exceed 10 trillion kilowatt-hours for the first time in 2025, reaching 10.4 trillion kilowatt-hours, a 5% year-on-year increase, setting a new global record for a single country [1][14][15] - This milestone reflects the strong resilience and large scale of the Chinese economy, driven by stable macroeconomic conditions, increased electrification, and sustained high temperatures [1][14][15] - Notably, electricity consumption in emerging industries such as new energy vehicles and the digital economy is growing rapidly, while high-energy-consuming industries are experiencing a slowdown, indicating a shift towards high-tech and high-value-added sectors [1][14][15] Group 6: Corporate Financial Health - Bosch, the world's largest automotive supplier, has warned that its operating profit margin will fall below 2% in 2025, significantly lower than its long-term target of 7% [1][4][15] - The company's revenue is approximately 91 billion euros, but actual revenue has declined when excluding acquisition impacts [1][4][15] - The profit reduction is primarily due to restructuring costs of 3.1 billion euros and market challenges, prompting Bosch to initiate layoffs to cope with the pressures of electrification, weak demand, and intense competition [1][4][15]

这对于库欣综合征患者而言，锐康迪的退出相当于断供了一款"救命药"。据媒体公开报道，一位服用了 四年奥唑司他的库欣综合征患者称，这几年下来，"吃掉了100万元"。 Recordati曾对奥唑司他在中国的销售抱有很高的期望。这款药物目前在国内尚无同类替代疗法，国内上 市后的价格约为8000元/盒，尽管中国国内售价为全球最低的市场之一，但一年下来平均治疗费用仍然 达到约20万元。 2025年8月，奥唑司他通过了2025年国家医保目录调整的初步形式审查目录。有专家称，该药物进入医 保目录的可能性很大，医保报销后，患者自费部分有望降到每月2000元以下。然而，最终的医保目录 中，该公司包括奥唑司他在内的三款药物均未成功纳入。 近日，意大利制药公司Recordati旗下100%控股的中国公司锐康迪正式进行注销备案，将彻底退出中国 市场。伴随着锐康迪的退出，该公司的几款罕见病药物也将停止对中国的供货，其中就包括中国仅有的 一款用于治疗库欣综合征的口服药物奥唑司他。 奥唑司他于2024年9月在中国国内获批，2025年4月正式在中国实现商业化，至今上市销售仅不到一年。 但自2021年起，该药物已经在博鳌乐城作为先行先试项目开始 ...

Core Viewpoint - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will result in the discontinuation of several rare disease medications, including the only oral drug for Cushing's syndrome, Osilodrostat [3][5]. Group 1: Company Actions - Ruikangdi's exit signifies a significant loss for Cushing's syndrome patients, as it is considered a "lifesaving drug" [5]. - Osilodrostat was approved in China in September 2024 and commercialized in April 2025, but has been available since 2021 as part of a pilot program [5]. - Recordati had high sales expectations for Osilodrostat in China, where it was priced at approximately 8,000 yuan per box, with annual treatment costs averaging around 200,000 yuan [5]. Group 2: Market Challenges - The drug's potential inclusion in the national medical insurance directory was anticipated, which could have reduced out-of-pocket costs for patients to below 2,000 yuan per month, but it ultimately was not included [5]. - The high cost of rare disease drug development and the limited patient population make pricing and reimbursement a significant challenge, especially in China where commercial insurance is still developing [6]. - Only about 50 patients in China are estimated to have purchased Osilodrostat, highlighting the drug's limited market penetration due to affordability issues [6]. Group 3: Industry Context - Recordati's exit is not an isolated incident; BioMarin also withdrew a rare disease treatment from the Chinese market in 2024, leaving patients without available options [7]. - The challenges faced by rare disease pharmaceutical companies include lengthy and costly market education and the financial burden on patients, many of whom struggle economically [7]. - Even drugs that are included in insurance plans can face supply issues, as seen with the drug Nitisinone, which experienced shortages despite being on the market for two years [7].

罕见病药研发成本高，使用人数少，定价高昂，支付往往依赖医保、商保在内的多层次支付体系。与一些大型制药公司相 比，产品管线并不丰富的中小规模企业生存状况尤为艰难。 近日，意大利制药公司Recordati旗下100%控股的中国公司锐康迪正式进行注销备案，将彻底退出中国市场。伴随着锐康迪 的退出，该公司的几款罕见病药物也将停止对中国的供货，其中就包括中国仅有的一款用于治疗库欣综合征的口服药物奥 唑司他。 奥唑司他于2024年9月在中国国内获批，2025年4月正式在中国实现商业化，至今上市销售仅不到一年。但自2021年起，该 药物已经在博鳌乐城作为先行先试项目开始使用。 近年来，业内不断呼吁加强对罕见病的关注，但与一些大型制药公司相比，产品管线并不丰富的专注于罕见病研发的中小 规模企业生存状况尤为艰难。 Recordati退出中国市场并不是孤例。2024年，制药公司BioMarin的一款治疗罕见病黏多糖贮积症IVA型的"孤儿药"正式退出 中国市场。该疾病的患者也曾面临无药可用的困局。 锐康迪总经理胡茂胜曾在去年10月的一次采访中表示，对于罕见病药企而言，产品上市后的挑战更大，医患教育与市场培 育耗时漫长且需要投入高昂 ...

Core Viewpoint - Recordati's subsidiary, Recondi, unexpectedly announced its exit from the Chinese market, citing recent market and regulatory dynamics, including the rejection of its drug Ozagrel for inclusion in the national medical insurance drug list [1][2]. Company Overview - Recondi, established in 2021, focused on rare diseases and had three approved drugs in China, with two commercialized. The company experienced rapid expansion but faced challenges in achieving profitability [3][16]. - The company had been actively hiring and promoting its products for inclusion in medical insurance while conducting education for doctors and patients [2][3]. Market Dynamics - The National Healthcare Security Administration has been increasing support for rare diseases, with approximately 100 rare disease drugs included in the national medical insurance drug list since 2018 [3]. - Despite the growing support for rare diseases, Recondi's products, including Ozagrel, did not make it into the insurance list, leading to their withdrawal from the market [3][7]. Product Details - Ozagrel, a key product for treating Cushing's syndrome, was priced at 8,008 yuan per box, significantly lower than global prices but still high for patients [6][7]. - The other product, Karglutan, had limited sales due to the availability of generic alternatives and high costs, making it unaffordable for many patients [6][10]. Patient Impact - The exit of Recondi has left many patients without access to critical medications, with some patients expressing regret and concern over the lack of alternatives [2][11]. - The high cost of Ozagrel and the absence of insurance coverage have made it difficult for patients to afford the treatment, with many waiting for it to be included in the insurance list [10][11]. Industry Challenges - The rare disease sector faces significant challenges, including high research and development costs, limited patient populations, and the need for extensive education and market cultivation [16][18]. - Recondi's experience reflects broader industry difficulties, as companies specializing in rare diseases often struggle to achieve sustainable business models without the support of insurance coverage [17][18].

经济观察报 记者 张铃 "我非常遗憾，我的很多病人没药可用了。"2026年1月13日，看到意大利制药集团Recordati旗下锐康迪（北京）医药有限公司（下称"锐康迪"）宣布退出中 国市场的消息后，中山大学附属第一医院内分泌科主任医师廖志红对经济观察报说。 锐康迪在2026年1月9日宣布，其已于2025年12月11日完成清算组备案，并进入清算程序，全部业务活动将于近期全面终止，未来将无法继续提供任何形式的 产品、服务或业务支持。 这是一家成立五年、专注罕见病的跨国药企中国商业子公司，旗下有三款罕见病药物在中国获批，其中两款实现商业化。近两年，锐康迪招兵买马，推动产 品进医保，同时开展医生和患者教育。 接受经济观察报采访的患者、医生、锐康迪前员工和罕见病企业人士，都对锐康迪的离开感到意外和遗憾。 关于退出中国市场的原因，锐康迪官方在1月13日向经济观察报出示的声明中提到："这一决定是基于近期的市场和监管动态，包括奥唑司他申请2025年国家 医保药品目录的否决结果。" 事实上，国家医保局一直在加大对罕见病的保障力度，2018年至今，已有约100种罕见病用药被纳入国家医保药品目录。 锐康迪有过一段激进扩张的时期，在 ...